|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date20 Sep 2013 |
|
MechanismH1 receptor antagonists |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date01 Apr 1994 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Japan |
First Approval Date29 Nov 1986 |
一项在健康成人中进行的STN1013800滴眼液多次给药,药代动力学研究
[Translation] A multiple-dose pharmacokinetic study of STN1013800 eye drops in healthy adults
在健康成人中研究每只眼接受STN1013800滴眼液多次眼部给药后羟甲唑啉的生物利用度。
[Translation] The bioavailability of oxymetazoline was studied in healthy adults after multiple ocular administration of STN1013800 eye drops to each eye.
0.1%STN1011403滴眼液治疗过敏性结膜炎的多中心随机评价者盲态阳性对照试验
[Translation] A multicenter randomized evaluator-blind positive controlled trial of 0.1% STN1011403 eye drops in the treatment of allergic conjunctivitis
以中国过敏性结膜炎患者为对象,验证0.1% STN1011403 滴眼液的有效性非劣于Alesion® LX 滴眼液0.1%以及0.1%盐酸奥洛他定滴眼液,并确认安全性。
[Translation] The efficacy of 0.1% STN1011403 eye drops was verified to be non-inferior to Alesion® LX eye drops 0.1% and 0.1% olopatadine hydrochloride eye drops in Chinese patients with allergic conjunctivitis, and the safety was confirmed.
以健康中国成年人为对象评价STN1013400 滴眼液的安全性及药代动力学的临床试验
[Translation] A clinical trial evaluating the safety and pharmacokinetics of STN1013400 eye drops in healthy Chinese adults
以中国健康成年受试者为对象,评价0.1%、0.5%和3% STN1013400滴眼液(1次1滴,1日1次,双眼滴眼7天)的安全性及药代动力学。
[Translation] The safety and pharmacokinetics of 0.1%, 0.5% and 3% STN1013400 eye drops (1 drop once a day, in both eyes for 7 days) were evaluated in healthy Chinese adult subjects.
100 Clinical Results associated with Santen Pharmaceutical (China) Co. Ltd.
0 Patents (Medical) associated with Santen Pharmaceutical (China) Co. Ltd.
100 Deals associated with Santen Pharmaceutical (China) Co. Ltd.
100 Translational Medicine associated with Santen Pharmaceutical (China) Co. Ltd.